More recently, in an ovarian carcinoma model, it has been confirmed that SDC1 and the tumor angiogenic B-FN isoform play pivotal roles in VM and that combined treatment using L19-IL2 and an anti-SDC1 46F2SIP antibody was effective in reducing the expression of EMT markers and loss of cancer stemness traits, which were correlated with the inhibition of VM in mice [119]. Here, IL2 is linked to cancer.